<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02968771</url>
  </required_header>
  <id_info>
    <org_study_id>METS</org_study_id>
    <nct_id>NCT02968771</nct_id>
  </id_info>
  <brief_title>Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT</brief_title>
  <acronym>METS</acronym>
  <official_title>Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze metabolomic pattern of patients after cardiac stress in&#xD;
      order to detect differences based on the type of stress (physical or pharmacological with&#xD;
      adenosine agonists) and result of test (positive or negative for ischemia) and to indentify&#xD;
      biochemical markers with prognostic value. Clinical data of enrolled patients regarding&#xD;
      demographics, cardiovascular risk factors, pretest probability and previous cardiovascular&#xD;
      disease will be recorded. Follow up will be at one, three and five years and will be&#xD;
      performed by clinical recordings or phone call when necessary. Blood samples of patients&#xD;
      undergoing myocardial perfusion SPECT (Single Photon Emission Computed Tomography) are taken&#xD;
      before, immediately after stress and 2h after stress. Serum samples will be analyzed by&#xD;
      nuclear magnetic resonance in order to know metabolomic profile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to analyze metabolomic pattern of patients after cardiac stress in&#xD;
      order to detect differences based on the type of stress (physical or pharmacological with&#xD;
      adenosine agonists) and result of test (positive or negative for ischemia) and to indentify&#xD;
      biochemical markers with prognostic value. Clinical data of enrolled patients regarding&#xD;
      demographics, cardiovascular risk factors, pretest probability and previous cardiovascular&#xD;
      disease will be recorded. Follow up will be at one, three and five years and will be&#xD;
      performed by clinical recordings or phone call when necessary. Blood samples of patients&#xD;
      undergoing myocardial perfusion SPECT are taken before, immediately after stress and 2h after&#xD;
      stress. Serum samples will be analyzed by nuclear magnetic resonance in order to know&#xD;
      metabolomic profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Result of myocardial perfusion SPECT: positive or negative for angina, ischemia or perfusion defect.</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolomic profile on NMR (Nuclear Magnetic Resonance ) analysis of serum sample</measure>
    <time_frame>6 month</time_frame>
    <description>Once all samples analyzed, in order to identify of specific patterns associated to any group (type of test or result of test).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined end point: Cardiovascular death, Myocardial infarction, Coronary revascularization.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined end point: Cardiovascular death, Myocardial infarction, Coronary revascularization.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined end point: Cardiovascular death, Myocardial infarction, Coronary revascularization.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina treatment initiation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina treatment initiation</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina treatment initiation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic profile on NMR analysis of serum sample</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic profile on NMR analysis of serum sample</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomic profile on NMR analysis of serum sample</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>Patients with Physical Cardiac Stress</arm_group_label>
    <description>Patients with Physical Cardiac Stress</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Physical and Pharmacological Cardiac Stress</arm_group_label>
    <description>Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Pharmacological Cardiac Stress</arm_group_label>
    <description>Patients with Pharmacological Cardiac Stress with adenosine agonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non intervention</intervention_name>
    <arm_group_label>Patients with Pharmacological Cardiac Stress</arm_group_label>
    <arm_group_label>Patients with Physical Cardiac Stress</arm_group_label>
    <arm_group_label>Patients with Physical and Pharmacological Cardiac Stress</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples without DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with prescription of cardiac perfusion SPECT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients men or women ≥ 18 years of age&#xD;
&#xD;
          -  Patients with prescription of cardiac perfusion SPECT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with loss of consciousness or confuse, not able to read the information and&#xD;
             to sign the writting consent&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Patients with dobutamine indications in the stress protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Task Force Members; Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines; Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers; Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. No abstract available. Erratum In: Eur Heart J. 2014 Sep 1;35(33):2260-1.</citation>
    <PMID>23996286</PMID>
  </reference>
  <reference>
    <citation>Liga R, Vontobel J, Rovai D, Marinelli M, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, Pizzi MN, Todiere G, Gimelli A, Chiappino D, Marraccini P, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Filardi PP, Fernandez-Golfin C, Rincon LM, Graner FP, de Graaf MA, Stehli J, Reyes E, Nkomo S, Maki M, Lorenzoni V, Turchetti G, Carpeggiani C, Puzzuoli S, Mangione M, Marcheschi P, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Underwood SR, Knuuti J, Kaufmann PA, Neglia D, Gaemperli O; EVINCI Study Investigators. Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population. Eur Heart J Cardiovasc Imaging. 2016 Sep;17(9):951-60. doi: 10.1093/ehjci/jew038. Epub 2016 Mar 18.</citation>
    <PMID>26992419</PMID>
  </reference>
  <reference>
    <citation>Mutuberria-Urdaniz M, Pizzi MN, Aguade-Bruix S, Candell-Riera J, Otaegui-Irurueta I. [Spastic coronary artery. Correlation of the myocardium at risk with scintigraphy and coronary angiography]. Rev Esp Med Nucl Imagen Mol. 2013 Jan;32(1):40-2. doi: 10.1016/j.remn.2011.12.004. Epub 2012 May 8. Spanish.</citation>
    <PMID>23177343</PMID>
  </reference>
  <reference>
    <citation>Weber KT. What can we learn from exercise testing beyond the detection of myocardial ischemia? Clin Cardiol. 1997 Aug;20(8):684-96. doi: 10.1002/clc.4960200805.</citation>
    <PMID>9259161</PMID>
  </reference>
  <reference>
    <citation>Candell-Riera J, Santana-Boado C, Castell-Conesa J, Aguade-Bruix S, Bermejo-Fraile B, Soler-Soler J. Dipyridamole administration at the end of an insufficient exercise Tc-99m MIBI SPECT improves detection of multivessel coronary artery disease in patients with previous myocardial infarction. Am J Cardiol. 2000 Mar 1;85(5):532-5. doi: 10.1016/s0002-9149(99)00806-1.</citation>
    <PMID>11078262</PMID>
  </reference>
  <reference>
    <citation>Candell-Riera J, Santana-Boado C, Castell-Conesa J, Aguade-Bruix S, Olona M, Palet J, Cortadellas J, Garcia-Burillo A, Soler-Soler J. Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease. J Am Coll Cardiol. 1997 Mar 1;29(3):531-6. doi: 10.1016/s0735-1097(96)00562-1.</citation>
    <PMID>9060889</PMID>
  </reference>
  <reference>
    <citation>Johnson SG, Peters S. Advances in pharmacologic stress agents: focus on regadenoson. J Nucl Med Technol. 2010 Sep;38(3):163-71. doi: 10.2967/jnmt.109.065581. Epub 2010 Aug 19.</citation>
    <PMID>20724531</PMID>
  </reference>
  <reference>
    <citation>Cassar A, Chareonthaitawee P, Rihal CS, Prasad A, Lennon RJ, Lerman LO, Lerman A. Lack of correlation between noninvasive stress tests and invasive coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease. Circ Cardiovasc Interv. 2009 Jun;2(3):237-44. doi: 10.1161/CIRCINTERVENTIONS.108.841056. Epub 2009 May 8.</citation>
    <PMID>20031721</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Sinovas A, Sanchez JA, Gonzalez-Loyola A, Barba I, Morente M, Aguilar R, Agullo E, Miro-Casas E, Esquerda N, Ruiz-Meana M, Garcia-Dorado D. Effects of substitution of Cx43 by Cx32 on myocardial energy metabolism, tolerance to ischaemia and preconditioning protection. J Physiol. 2010 Apr 1;588(Pt 7):1139-51. doi: 10.1113/jphysiol.2009.186577. Epub 2010 Feb 15.</citation>
    <PMID>20156849</PMID>
  </reference>
  <reference>
    <citation>Caselli C, Rovai D, Lorenzoni V, Carpeggiani C, Teresinska A, Aguade S, Todiere G, Gimelli A, Schroeder S, Casolo G, Poddighe R, Pugliese F, Le Guludec D, Valente S, Sambuceti G, Perrone-Filardi P, Del Ry S, Marinelli M, Nekolla S, Pietila M, Lombardi M, Sicari R, Scholte A, Zamorano J, Kaufmann PA, Underwood SR, Knuuti J, Giannessi D, Neglia D; EVINCI Study Investigators. A New Integrated Clinical-Biohumoral Model to Predict Functionally Significant Coronary Artery Disease in Patients With Chronic Chest Pain. Can J Cardiol. 2015 Jun;31(6):709-16. doi: 10.1016/j.cjca.2015.01.035. Epub 2015 Feb 2.</citation>
    <PMID>26022987</PMID>
  </reference>
  <reference>
    <citation>Barba I, Jaimez-Auguets E, Rodriguez-Sinovas A, Garcia-Dorado D. 1H NMR-based metabolomic identification of at-risk areas after myocardial infarction in swine. MAGMA. 2007 Dec;20(5-6):265-71. doi: 10.1007/s10334-007-0097-8. Epub 2007 Dec 20.</citation>
    <PMID>18095012</PMID>
  </reference>
  <reference>
    <citation>Barba I, de Leon G, Martin E, Cuevas A, Aguade S, Candell-Riera J, Barrabes JA, Garcia-Dorado D. Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med. 2008 Jul;60(1):27-32. doi: 10.1002/mrm.21632.</citation>
    <PMID>18581408</PMID>
  </reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>February 22, 2019</last_update_submitted>
  <last_update_submitted_qc>February 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Cardiac perfusion SPECT</keyword>
  <keyword>Metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02968771
org study id: METS
nct id: NCT02968771
lead sponsor: 
has dmc: No
The aim of this study is to analyze metabolomic pattern of patients after cardiac stress in
      order to detect differences based on the type of stress (physical or pharmacological with
      adenosine agonists) and result of test (positive or negative for ischemia) and to indentify
      biochemical markers with prognostic value. Clinical data of enrolled patients regarding
      demographics, cardiovascular risk factors, pretest probability and previous cardiovascular
      disease will be recorded. Follow up will be at one, three and five years and will be
      performed by clinical recordings or phone call when necessary. Blood samples of patients
      undergoing myocardial perfusion SPECT (Single Photon Emission Computed Tomography) are taken
      before, immediately after stress and 2h after stress. Serum samples will be analyzed by
      nuclear magnetic resonance in order to know metabolomic profile.
The aim of this study is to analyze metabolomic pattern of patients after cardiac stress in
      order to detect differences based on the type of stress (physical or pharmacological with
      adenosine agonists) and result of test (positive or negative for ischemia) and to indentify
      biochemical markers with prognostic value. Clinical data of enrolled patients regarding
      demographics, cardiovascular risk factors, pretest probability and previous cardiovascular
      disease will be recorded. Follow up will be at one, three and five years and will be
      performed by clinical recordings or phone call when necessary. Blood samples of patients
      undergoing myocardial perfusion SPECT are taken before, immediately after stress and 2h after
      stress. Serum samples will be analyzed by nuclear magnetic resonance in order to know
      metabolomic profile.
observational model: Case-Only
time perspective: Prospective
measure: Result of myocardial perfusion SPECT: positive or negative for angina, ischemia or perfusion defect.
time frame: 2 days
measure: Metabolomic profile on NMR (Nuclear Magnetic Resonance ) analysis of serum sample
time frame: 6 month
description: Once all samples analyzed, in order to identify of specific patterns associated to any group (type of test or result of test).
measure: Combined end point: Cardiovascular death, Myocardial infarction, Coronary revascularization.
time frame: 1 year
measure: Combined end point: Cardiovascular death, Myocardial infarction, Coronary revascularization.
time frame: 3 years
measure: Combined end point: Cardiovascular death, Myocardial infarction, Coronary revascularization.
time frame: 5 years
measure: Angina treatment initiation
time frame: 1 year
measure: Angina treatment initiation
time frame: 3 years
measure: Angina treatment initiation
time frame: 5 years
measure: Metabolomic profile on NMR analysis of serum sample
time frame: 1 year
measure: Metabolomic profile on NMR analysis of serum sample
time frame: 3 years
measure: Metabolomic profile on NMR analysis of serum sample
time frame: 5 years
arm group label: Patients with Physical Cardiac Stress
description: Patients with Physical Cardiac Stress
arm group label: Patients with Physical and Pharmacological Cardiac Stress
description: Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
arm group label: Patients with Pharmacological Cardiac Stress
description: Patients with Pharmacological Cardiac Stress with adenosine agonist
intervention type: Other
intervention name: Non intervention
arm group label: Patients with Pharmacological Cardiac Stress
arm group label: Patients with Physical Cardiac Stress
arm group label: Patients with Physical and Pharmacological Cardiac Stress
Samples without DNA
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
facility: 
country: Spain
citation: Task Force Members; Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ; ESC Committee for Practice Guidelines; Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S; Document Reviewers; Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30. No abstract available. Erratum In: Eur Heart J. 2014 Sep 1;35(33):2260-1.
PMID: 23996286
citation: Liga R, Vontobel J, Rovai D, Marinelli M, Caselli C, Pietila M, Teresinska A, Aguade-Bruix S, Pizzi MN, Todiere G, Gimelli A, Chiappino D, Marraccini P, Schroeder S, Drosch T, Poddighe R, Casolo G, Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S, Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Filardi PP, Fernandez-Golfin C, Rincon LM, Graner FP, de Graaf MA, Stehli J, Reyes E, Nkomo S, Maki M, Lorenzoni V, Turchetti G, Carpeggiani C, Puzzuoli S, Mangione M, Marcheschi P, Giannessi D, Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Underwood SR, Knuuti J, Kaufmann PA, Neglia D, Gaemperli O; EVINCI Study Investigators. Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population. Eur Heart J Cardiovasc Imaging. 2016 Sep;17(9):951-60. doi: 10.1093/ehjci/jew038. Epub 2016 Mar 18.
PMID: 26992419
citation: Mutuberria-Urdaniz M, Pizzi MN, Aguade-Bruix S, Candell-Riera J, Otaegui-Irurueta I. [Spastic coronary artery. Correlation of the myocardium at risk with scintigraphy and coronary angiography]. Rev Esp Med Nucl Imagen Mol. 2013 Jan;32(1):40-2. doi: 10.1016/j.remn.2011.12.004. Epub 2012 May 8. Spanish.
PMID: 23177343
citation: Weber KT. What can we learn from exercise testing beyond the detection of myocardial ischemia? Clin Cardiol. 1997 Aug;20(8):684-96. doi: 10.1002/clc.4960200805.
PMID: 9259161
citation: Candell-Riera J, Santana-Boado C, Castell-Conesa J, Aguade-Bruix S, Bermejo-Fraile B, Soler-Soler J. Dipyridamole administration at the end of an insufficient exercise Tc-99m MIBI SPECT improves detection of multivessel coronary artery disease in patients with previous myocardial infarction. Am J Cardiol. 2000 Mar 1;85(5):532-5. doi: 10.1016/s0002-9149(99)00806-1.
PMID: 11078262
citation: Candell-Riera J, Santana-Boado C, Castell-Conesa J, Aguade-Bruix S, Olona M, Palet J, Cortadellas J, Garcia-Burillo A, Soler-Soler J. Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease. J Am Coll Cardiol. 1997 Mar 1;29(3):531-6. doi: 10.1016/s0735-1097(96)00562-1.
PMID: 9060889
citation: Johnson SG, Peters S. Advances in pharmacologic stress agents: focus on regadenoson. J Nucl Med Technol. 2010 Sep;38(3):163-71. doi: 10.2967/jnmt.109.065581. Epub 2010 Aug 19.
PMID: 20724531
citation: Cassar A, Chareonthaitawee P, Rihal CS, Prasad A, Lennon RJ, Lerman LO, Lerman A. Lack of correlation between noninvasive stress tests and invasive coronary vasomotor dysfunction in patients with nonobstructive coronary artery disease. Circ Cardiovasc Interv. 2009 Jun;2(3):237-44. doi: 10.1161/CIRCINTERVENTIONS.108.841056. Epub 2009 May 8.
PMID: 20031721
citation: Rodriguez-Sinovas A, Sanchez JA, Gonzalez-Loyola A, Barba I, Morente M, Aguilar R, Agullo E, Miro-Casas E, Esquerda N, Ruiz-Meana M, Garcia-Dorado D. Effects of substitution of Cx43 by Cx32 on myocardial energy metabolism, tolerance to ischaemia and preconditioning protection. J Physiol. 2010 Apr 1;588(Pt 7):1139-51. doi: 10.1113/jphysiol.2009.186577. Epub 2010 Feb 15.
PMID: 20156849
citation: Caselli C, Rovai D, Lorenzoni V, Carpeggiani C, Teresinska A, Aguade S, Todiere G, Gimelli A, Schroeder S, Casolo G, Poddighe R, Pugliese F, Le Guludec D, Valente S, Sambuceti G, Perrone-Filardi P, Del Ry S, Marinelli M, Nekolla S, Pietila M, Lombardi M, Sicari R, Scholte A, Zamorano J, Kaufmann PA, Underwood SR, Knuuti J, Giannessi D, Neglia D; EVINCI Study Investigators. A New Integrated Clinical-Biohumoral Model to Predict Functionally Significant Coronary Artery Disease in Patients With Chronic Chest Pain. Can J Cardiol. 2015 Jun;31(6):709-16. doi: 10.1016/j.cjca.2015.01.035. Epub 2015 Feb 2.
PMID: 26022987
citation: Barba I, Jaimez-Auguets E, Rodriguez-Sinovas A, Garcia-Dorado D. 1H NMR-based metabolomic identification of at-risk areas after myocardial infarction in swine. MAGMA. 2007 Dec;20(5-6):265-71. doi: 10.1007/s10334-007-0097-8. Epub 2007 Dec 20.
PMID: 18095012
citation: Barba I, de Leon G, Martin E, Cuevas A, Aguade S, Candell-Riera J, Barrabes JA, Garcia-Dorado D. Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease. Magn Reson Med. 2008 Jul;60(1):27-32. doi: 10.1002/mrm.21632.
PMID: 18581408
responsible party type: Sponsor
mesh term: Heart Diseases
mesh term: Myocardial Ischemia
mesh term: Coronary Artery Disease
sharing ipd: No